Evidence map›Paper›PMID 40704349›Full record

ArticleTanaffos2024

Changes in Pharmacological Approach to COVID-19 in a Referral Hospital in Tehran During Two Years.

Seyed Mehran Marashian, Mohsen Sadeghi, Somayeh Lookzadeh, Azadeh Moradkhani, Akram Qanavati, Zeinab Chaghervand, Sanaz Soleimani, Farnaz Hadipour, Maryam Shahmorad, Mahboobeh Mohammadi and 6 more

Abstract read
PubMed Full text at PMC
In one paragraph

Article in Tanaffos, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Seyed Mehran MarashianChronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mohsen SadeghiChronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Somayeh LookzadehChronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Azadeh MoradkhaniChronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Akram QanavatiChronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Zeinab ChaghervandChronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Sanaz SoleimaniChronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Farnaz HadipourChronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Maryam ShahmoradChronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Mahboobeh MohammadiChronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Shirin EsmaeiliChronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Latifeh JavadiChronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hooman SharifiTobacco Prevention and Control Research Center, NRITLD, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Esmaeil IdaniChronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Hamidreza JamaatiChronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Alireza EslaminejadChronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The current study attempts to look at the trend of medication prescription among inpatients with COVID-19 by comparing two groups of them who were admitted into our hospital at separate times at around two-year intervals. Materials and Methods: Through a retrospective cross-sectional design, the current study enrolled hospitalized cases from two separate periods including winter 2019 and summer 2021 to compare some characteristics of COVID-19 in addition to sex and age distribution as well as the approach and management and their changes as the time passed. Results: Remdesivir was raised to be the most commonly used medication for COVID-19 after one and a half years when approved by the FDA in this regard. Tocilizumab was prescribed for just less than 6% of earlier pandemics in winter 2019 while used in more than half of hospitalizations in 2021. After two years, corticosteroids are used in 98.6% of the cases at least in our center. Conclusion: Exact medication administration to target COVID-19 and accurate vaccination in addition to "Herd immunity" among the global population seems to be the chief secret of the current success at least for partial control of the disease now.

Indexed as

CorticosteroidsCOVID-19ManagementMedicationsRemdesivirTocilizumab

Identifiers

PMID40704349
PMCPMC12281348

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.